Surgery after drug treatment for advanced stomach cancer
This trial is for people with advanced stomach cancer that has shrunk after initial chemotherapy or targeted therapy. It compares whether adding surgery to continued medical treatment is better than staying on medical treatment alone, with the goal of improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have stomach or gastroesophageal junction cancer that has spread to other parts of the body
- Your cancer is not removable by surgery at diagnosis, but after 4-6 cycles of first-line drug therapy, it has shrunk (complete or partial response)
- Your doctors think it is now possible to remove all visible cancer with surgery
- You are in good general health, with a performance status of 0 or 1, and have adequate blood counts and liver and kidney function
- You have not had prior systemic treatment for advanced cancer before this therapy, and you have not had prior radiation to the stomach
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at laparoscopic (keyhole) total stomach removal for people with advanced stomach cancer in the upper or middle part of the stomach. It aims to see whether this operation approach is safe and useful based on your tumor stage and overall health.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
This trial compares two approaches for stomach cancer that has spread to the abdominal lining after initial treatment (conversion therapy). One group receives surgery to remove the cancer, while the other does not. The goal is to see if surgery improves outcomes in patients who responded well to the initial treatment.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
Hear when a new Advanced Metastatic Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.